Advertisement
LITS vs ONCY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LITS is a StrongBuy and ONCY is a StrongBuy.
LITS sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for LITS moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 68 cases where LITS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +6.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where LITS advanced for three days, in 165 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 92 of 119 cases where LITS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for LITS moved out of overbought territory on September 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In 14 of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LITS as a result. In 69 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for LITS turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 33 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LITS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LITS broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. LITS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.973) is normal, around the industry mean (2.973). P/E Ratio (-0.578) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (3.410) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LITS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ONCY's RSI Indicator ascends from oversold territory
The RSI Indicator for ONCY moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 33 of the 42 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 64 cases where ONCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ONCY just turned positive on October 22, 2026. Looking at past instances where ONCY's MACD turned positive, the stock continued to rise in 28 of 47 cases over the following month. The odds of a continued upward trend are 60%.
Following a +3.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCY advanced for three days, in 147 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
ONCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ONCY entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-10.342) is normal, around the industry mean (2.973). P/E Ratio (-1.429) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. ONCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LITS | ONCY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 94 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 50 | 90 | |
P/E GROWTH RATING 1..100 | 59 | 13 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ONCY's Valuation (13) in the Biotechnology industry is significantly better than the same rating for LITS (79) in the Pharmaceuticals Other industry. This means that ONCY’s stock grew significantly faster than LITS’s over the last 12 months.
ONCY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as LITS (100) in the Pharmaceuticals Other industry. This means that ONCY’s stock grew similarly to LITS’s over the last 12 months.
ONCY's SMR Rating (100) in the Biotechnology industry is in the same range as LITS (100) in the Pharmaceuticals Other industry. This means that ONCY’s stock grew similarly to LITS’s over the last 12 months.
LITS's Price Growth Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for ONCY (90) in the Biotechnology industry. This means that LITS’s stock grew somewhat faster than ONCY’s over the last 12 months.
ONCY's P/E Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for LITS (59) in the Pharmaceuticals Other industry. This means that ONCY’s stock grew somewhat faster than LITS’s over the last 12 months.
| LITS | ONCY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 77% | N/A |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 60% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 87% |
| Advances ODDS (%) | 2 days ago 73% | 2 days ago 76% |
| Declines ODDS (%) | 9 days ago 84% | 4 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 77% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LITS’s FA Score shows that 0 FA rating(s) are green while ONCY’s FA Score has 2 green FA rating(s).
- LITS’s FA Score: 0 green, 5 red.
- ONCY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LITS’s TA Score shows that 4 TA indicator(s) are bullish while ONCY’s TA Score has 5 bullish TA indicator(s).
- LITS’s TA Score: 4 bullish, 5 bearish.
- ONCY’s TA Score: 5 bullish, 2 bearish.
Price Growth
LITS (@Biotechnology) experienced а +5.98% price change this week, while ONCY (@Biotechnology) price change was -8.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
LITS is expected to report earnings on Nov 13, 2026.
ONCY is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LITS and
Correlation & Price change
A.I.dvisor indicates that over the last year, LITS has been loosely correlated with GOSS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LITS jumps, then GOSS could also see price increases.
| Ticker / NAME | Correlation To LITS | 1D Price Change % | ||
|---|---|---|---|---|
| LITS | 100% | -4.03% | ||
| GOSS - LITS | 45% Loosely correlated | -3.37% | ||
| HYPD - LITS | 45% Loosely correlated | -5.81% | ||
| RXRX - LITS | 37% Loosely correlated | -1.65% | ||
| CNTN - LITS | 35% Loosely correlated | -3.63% | ||
| CRSP - LITS | 33% Loosely correlated | -1.01% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ACSV | 48.47 | 0.53 | +1.10% |
| American Century Small Cap Value Insights ETF (ACSV) | |||
| MLRG | 105.83 | -1.30 | -1.21% |
| iShares MSCI USA ETF (MLRG) | |||
| PRMR | 28.30 | -0.36 | -1.26% |
| PeakShares RMR Prime Equity ETF (PRMR) | |||
| KSTR | 18.85 | -0.69 | -3.53% |
| KraneShares China Technology & Semiconductor STAR 50 Index ETF (KSTR) | |||
| ARKI | 22.30 | -1.93 | -7.98% |
| ARK DIET Q2 Buffer ETF (ARKI) | |||